Acrolein
CAS 107-02-8
Acrolein (CAS 107-02-8) is a pharmaceutical compound with 3 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | Potency | 42750.53333333333 nM | 6 | - |
| - | EC50 | 12943.07 nM | 4 | - |
| - | IC50 | 50120.1875 nM | 4 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPA1 TRPA1 |
Agonist | 5.300000190734863 pEC50 | 16564016 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acrolein used for in pharmaceutical contexts?
Acrolein (CAS 107-02-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acrolein?
No adverse-event association or SIDER side-effect rows are rendered for Acrolein in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acrolein also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Acrolein with EU status "prohibited".
What clinical phase is Acrolein in?
No phase 1-4 clinical development badge is rendered for Acrolein because the matched compound identifier rows do not contain a max-phase value.